Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Varespladib attenuates Naja atra -induced acute liver injury via reversing Nrf2 signaling-mediated ferroptosis and mitochondrial dysfunction

Open access

Abstract

Objective: To investigate the protective effects of varespladib against Naja atra-induced acute liver injury (ALI) and to elucidate the toxic mechanism of snake venom phospholipase A2 (SVPLA2)-induced hepatic oxidative stress, with a particular focus on the role of Nrf2 signaling and its downstream pathways.Methods: A combination of in vivo and in vitro models of N. atra envenomation was employed to assess liver injury, oxidative stress, and mitochondrial dysfunction. The interaction between SVPLA2 and Nrf2 was analyzed, and the effects of varespladib treatment on these processes were evaluated using histological analysis, biochemical assays, and molecular techniques targeting oxidative stress, ferroptosis, mitophagy, and apoptosis.Results: Varespladib significantly alleviated N. atra-induced ALI. SVPLA2 was found to directly bind to Nrf2, leading to severe oxidative stress. This oxidative stress initiated a cascade involving Nrf2-mediated ferroptosis, mitochondrial dysfunction, excessive mitophagy, and mitochondria-dependent apoptosis. Treatment with varespladib effectively reversed these pathological events by inhibiting SVPLA2 activity.Conclusion: Varespladib shows strong therapeutic potential for N. atra envenomation by targeting SVPLA2. Nrf2 was identified as a direct toxic target of SVPLA2, and Nrf2-mediated ferroptosis and mitochondrial dysfunction were key mechanisms underlying SVPLA2-induced hepatic injury.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/13510002.2025.2507557

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Schematic diagram of experimental design. (By Figdraw).
Figure 1. Schematic diagram of experimental design. (By Figdraw).CC BY-NC · PubMed Central
Figure 2. Varespladib effectively mitigates N. atra-induced ALI. (A) H&E staining was performed on liver tissue sections. Inflammatory cell infiltration is marked with a black arrow, liver sinus congestion is marked with blue arrows, and central venous congestion is marked with yellow arrows. (B) PAS staining of liver sections. (C–E) The liver function indicators. Scale bar, 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. NS group. #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. NA group. &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. NA + Var-L group. ns, not significant.
Figure 2. Varespladib effectively mitigates N. atra-induced ALI. (A) H&E staining was performed on liver tissue sections. Inflammatory cell infiltration is marked with a black arrow, liver sinus congestion is marked with blue arrows, and central venous congestion is marked with yellow arrows. (B) PAS staining of liver sections. (C–E) The liver function indicators. Scale bar, 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. NS group. #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. NA group. &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. NA + Var-L group. ns, not significant.CC BY-NC · PubMed Central
Figure 3. Varespladib alleviates N. atra-induced liver inflammation. (A–B) IHC was used to detect the expressions of inflammation factors in liver sections. (C–D) The quantification of the IHC images. (E) White blood cell count in a whole blood sample of each animal model group. Scale bar, 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. NS group. #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. NA group. &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. NA + Var-L group. ns, not significant.
Figure 3. Varespladib alleviates N. atra-induced liver inflammation. (A–B) IHC was used to detect the expressions of inflammation factors in liver sections. (C–D) The quantification of the IHC images. (E) White blood cell count in a whole blood sample of each animal model group. Scale bar, 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. NS group. #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. NA group. &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. NA + Var-L group. ns, not significant.CC BY-NC · PubMed Central
Figure 4. Varespladib treatment improves oxidative stress in the livers. (A–H) Detection of oxidative stress indicators in liver tissue. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. NS group. #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. NA group. &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. NA + Var-L group. ns, not significant.
Figure 4. Varespladib treatment improves oxidative stress in the livers. (A–H) Detection of oxidative stress indicators in liver tissue. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. NS group. #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. NA group. &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. NA + Var-L group. ns, not significant.CC BY-NC · PubMed Central
Figure 5. SVPLA2 directly binds to Nrf2. (A) The interaction of SVPLA2 with the Nrf2 protein in molecular docking analysis. (B–G) A 100-ns MDS between SVPLA2 and Nrf2. (H) Protein levels of Nrf2, NQO-1 and HO-1 were measured by Western blot analysis in L02 cells, (I-K) and the quantitative maps were created. (L) Co-IP between SVPLA2 and Nrf2. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.
Figure 5. SVPLA2 directly binds to Nrf2. (A) The interaction of SVPLA2 with the Nrf2 protein in molecular docking analysis. (B–G) A 100-ns MDS between SVPLA2 and Nrf2. (H) Protein levels of Nrf2, NQO-1 and HO-1 were measured by Western blot analysis in L02 cells, (I-K) and the quantitative maps were created. (L) Co-IP between SVPLA2 and Nrf2. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.CC BY-NC · PubMed Central
Figure 6. Cell viability assay and validation of the efficiency of Nrf2 knockdown. (A) Determination of the IC50 of N.atra venom on L02 cells (μg/mL); (B) Determination of the inhibitory concentration of Varespladib (μg/mL) against N. atra venom according to the N.atra venom IC50 value. (C–D) Validation of Nrf2 knockdown efficiency at protein level and mRNA level. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.
Figure 6. Cell viability assay and validation of the efficiency of Nrf2 knockdown. (A) Determination of the IC50 of N.atra venom on L02 cells (μg/mL); (B) Determination of the inhibitory concentration of Varespladib (μg/mL) against N. atra venom according to the N.atra venom IC50 value. (C–D) Validation of Nrf2 knockdown efficiency at protein level and mRNA level. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.CC BY-NC · PubMed Central
Figure 7. Varespladib relieves N. atra venom-induced oxidative stress in L02 cells. Blockade of Nrf2 abolishes the hepatoprotective effects of varespladib. (A-H) Detection of oxidative stress indicators in L02 cells. (I) The ROS content in L02 cells was determined by immunofluorescence. Scale bar, 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.
Figure 7. Varespladib relieves N. atra venom-induced oxidative stress in L02 cells. Blockade of Nrf2 abolishes the hepatoprotective effects of varespladib. (A-H) Detection of oxidative stress indicators in L02 cells. (I) The ROS content in L02 cells was determined by immunofluorescence. Scale bar, 100 μm. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.CC BY-NC · PubMed Central
Figure 8. Varespladib reverses N. atra-induced ferroptosis via Nrf2 signaling. (A) Determination of iron ion content in liver tissue. (B) Protein levels of GPX4 and ACSL4 were measured by Western blot analysis in L02 cells, (C–D) and the quantitative maps were created. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.
Figure 8. Varespladib reverses N. atra-induced ferroptosis via Nrf2 signaling. (A) Determination of iron ion content in liver tissue. (B) Protein levels of GPX4 and ACSL4 were measured by Western blot analysis in L02 cells, (C–D) and the quantitative maps were created. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.CC BY-NC · PubMed Central
Figure 9. Varespladib relieves N. atra-induced mitochondrial dysfunction and suppresses N. atra-induced excessive mitophagy via Nrf2 signaling. (A) ATP production in L02 cells. (B) CS activity in L02 cells. (C) Mitochondrial ROS in L02 cells. (D) MMP in L02 cells. (E) Protein levels of PINK1, Parkin, and LC3-II/I were measured by Western blot analysis in L02 cells. (F–H) and the quantitative maps were created. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.
Figure 9. Varespladib relieves N. atra-induced mitochondrial dysfunction and suppresses N. atra-induced excessive mitophagy via Nrf2 signaling. (A) ATP production in L02 cells. (B) CS activity in L02 cells. (C) Mitochondrial ROS in L02 cells. (D) MMP in L02 cells. (E) Protein levels of PINK1, Parkin, and LC3-II/I were measured by Western blot analysis in L02 cells. (F–H) and the quantitative maps were created. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.CC BY-NC · PubMed Central
Figure 10. Varespladib inhibits N. atra-induced mitochondria-mediated apoptosis via Nrf2 signaling. (A) Apoptosis was detected by flow cytometry. (B) Protein levels of Cleaved-Caspase 9 and Cleaved-Caspase 3 were measured by Western blot analysis in L02 cells. (C) Protein levels of Cyt c, Bax, and Bcl-2 were measured by Western blot analysis in L02 cells. (D-I) The quantitative maps of proteins were created. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.
Figure 10. Varespladib inhibits N. atra-induced mitochondria-mediated apoptosis via Nrf2 signaling. (A) Apoptosis was detected by flow cytometry. (B) Protein levels of Cleaved-Caspase 9 and Cleaved-Caspase 3 were measured by Western blot analysis in L02 cells. (C) Protein levels of Cyt c, Bax, and Bcl-2 were measured by Western blot analysis in L02 cells. (D-I) The quantitative maps of proteins were created. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, not significant.CC BY-NC · PubMed Central
Figure 11. Schematic representation of SVPLA2 target Nrf2 trigger ferroptosis and mitochondrial dysfunction (By Figdraw).
Figure 11. Schematic representation of SVPLA2 target Nrf2 trigger ferroptosis and mitochondrial dysfunction (By Figdraw).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Cited by

See all 14

Metadata

Authors
Liu, J., Wang, L., Xie, M., Zhao, W., Sun, J., Jin, Y., Liu, M., Zhao, J., Cheng, L., Wen, C., Bi, X., & Huang, C.
Affiliations
  • Nanchang University (CN)
  • Jilin Medical University (CN)
Corresponding author
Huang, Chunhong
Venue
Redox Report
Published
2025-05-21
Volume
30
Issue
1
Pages
2507557-2507557
ISSN
  • 1351-0002 (ISSN-L)
  • 1743-2928
OpenAlex
W4410576340
Cited by
13
References
76
Citations by year
2026: 13
FWCI
7.64
Type
journal article
Language
en
Open access
Locations
  • Redox Report (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangxi Province
  • Natural Science Fund Program of Science and Technology Department of Jilin
  • Innovation Project of College Students in Jilin Province
  • Innovation Project of Jilin Medical College Students
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Venomous Animal Envenomation and Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Pharmacology (medical) › Healthcare and Venom Research
Keywords
varespladib, Naja atra, snake venom phospholipase A2, acute liver injury, ferroptosis, Nrf2 signaling, mitochondrial dysfunction, oxidative stress, mitophagy, apoptosis, envenomation, hepatoprotection
MeSH terms
Naja naja, Ferroptosis, Animals, Elapid Venoms, Liver, Male, Mitochondria, Signal Transduction, Apoptosis, Oxidative Stress, NF-E2-Related Factor 2, Mice, Phospholipases A2, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Varespladib attenuates Naja atra -induced acute liver injury via reversing Nrf2 signaling-mediated ferroptosis and mitochondrial dysfunction. https://app.cochat.ai/papers/10.1080/13510002.2025.2507557
The paper
Liu, J., Wang, L., Xie, M., Zhao, W., Sun, J., Jin, Y., Liu, M., Zhao, J., Cheng, L., Wen, C., Bi, X., & Huang, C. (2025). Varespladib attenuates Naja atra -induced acute liver injury via reversing Nrf2 signaling-mediated ferroptosis and mitochondrial dysfunction. Redox Report. https://doi.org/10.1080/13510002.2025.2507557

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.